Fed. Circ. Ruling Clears Path For Longer Drug Patent Terms
Law360 (January 25, 2019, 10:04 PM EST) -- The Federal Circuit has given some patent owners, especially those in the pharmaceutical industry, a chance to obtain potentially lucrative extensions on the life of their patents by striking down U.S. Patent and Trademark Office regulations the court said "unfairly penalize applicants."
The appeals court ruled Wednesday that the patent office exceeded its statutory authority by imposing rules that in some situations restricted the availability of patent term adjustment, or time added to the life of patents to make up for delays during prosecution.
The patent owner in the case, Supernus Pharmaceuticals Inc., is seeking to extend the term of its...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!